References
- Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–2919.
- Sorror ML, Logan BR, Zhu X, et al. Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2015;21(8):1479–1487.
- Thakar MS, Broglie L, Logan B, et al. The hematopoietic cell transplant comorbidity index predicts survival after allogeneic transplant for nonmalignant diseases. Blood. 2019;133(7):754–762.
- Smith AR, Majhail NS, MacMillan ML, et al. Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients. Blood. 2011;117(9):2728–2734.
- Friend BD, Tang K, Markovic D, et al. Identifying risk factors associated with worse outcomes in adolescents and young adults undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2019;66(12):e27940.
- Broglie L, Ruiz J, Jin Z, et al. Limitations of applying the hematopoietic cell transplantation comorbidity index in pediatric patients receiving allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 2021;27(1):74.e1–74.e9.
- Wood W, Deal A, Whitley J, et al. Usefulness of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in predicting outcomes for adolescents and young adults with hematologic malignancies undergoing allogeneic stem cell transplant. Pediatr Blood Cancer. 2011;57(3):499–505.